339 results on '"Jayarajan, Pradeep"'
Search Results
2. Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
3. Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling
4. Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
5. Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization
6. Hits and misses with animal models of narcolepsy and the implications for drug discovery
7. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
8. Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design
9. Role of Onset of Diabetes on Development of Cognitive Impairment in Rats
10. 0609 Samelisant, Histamine 3 Receptor Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy
11. Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease
12. 5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids
13. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
14. SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
15. Effects of Masupirdine (SUVN‐502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer’s Disease: A Post Hoc Analysis
16. SUVN‐I7016031: A Novel M 1 ‐receptor Positive Allosteric Modulator (M 1 ‐PAM) for the treatment of Parkinson's Disease Associated Dementia
17. Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72 s (DRL-72 s) schedule in rats: Involvement of the serotonergic receptors in restoring the deficits
18. α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain
19. Simultaneous monitoring of electroencephalographic characteristics in animals subjected to behavioral tests: a preclinical investigation
20. Comparison of manual and automated filaments for evaluation of neuropathic pain behavior in rats
21. Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task
22. Comparison of whole body and head out plethysmography using respiratory stimulant and depressant in conscious rats
23. Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
24. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain
25. 0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy
26. Masupirdine (SUVN-502), A Serotonin Receptor Sub-Type 6 Antagonist for the Potential Treatment of Agitation and Psychosis in Patients with Dementia of Alzheimer’s Type (P1-1.Virtual)
27. Chronic treatment with a selective 5-HT6 receptor antagonist alters the behavioral and neurochemical effects of ethanol in young adult rats
28. Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study
29. Effect of Age, Cognitive Impairment Severity, and Duration of Disease on Efficacy of Masupirdine in Moderate Alzheimer's Disease Patients: A Post Hoc Analysis of a Phase-2 Randomized Placebo Controlled Study Results
30. Metformin, a calorie restriction mimetic for the treatment of Alzheimer’s disease: A preclinical investigation
31. Masupirdine (SUVN‐502): A promising clinical candidate for the management of agitation in Alzheimer’s dementia
32. 1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4 H ‐thiazolo[5,4‐ c ]pyridin‐5‐yl]propan‐1‐one: a Histamine H 3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition
33. 005 Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist in animal models of sleep disorders
34. 506 Samelisant: Baseline Characteristics from a Phase 2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy
35. Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
36. Masupirdine (SUVN‐502): Novel treatment option for the management of behavioral and psychological symptoms in patients with Alzheimer’s disease
37. Masupirdine (SUVN‐502): A pure 5‐HT 6 receptor antagonist ameliorates aggression‐like behavior in animal models
38. SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits
39. Potential benefits of Masupirdine (SUVN-502) on Behavioral and Psychological symptoms in patients with moderate Alzheimer’s Disease (5090)
40. Masupirdine (SUVN-502), a 5-HT6 receptor antagonist in combination with Donepezil and Memantine in moderate Alzheimer’s patients (5514)
41. 1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition
42. P3-434: SUVN-502: A PURE 5-HT6 RECEPTOR ANTAGONIST ATTENUATES MEMORY DEFICITS INDUCED BY DIVERSE CHALLENGES
43. P1-089: SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION): FIRST-IN-CLASS AND A PROMISING NEW APPROACH FOR THE SYMPTOMATIC TREATMENT OF ALZHEIMER'S DISEASE DEMENTIA
44. P2-083: SUVN-502: A PURE 5-HT6 RECEPTOR ANTAGONIST AMELIORATES SENILE DEMENTIA IN ANIMAL MODELS
45. 0120 SUVN-G3031, a Novel, Potent and Selective Histamine H3 Receptor Inverse Agonist for the Treatment of Narcolepsy: Preclinical Characterization
46. 0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study
47. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity
48. P2‐080: SUVN‐502: A PURE 5‐HT 6 ANTAGONIST AMELIORATES MEMORY DEFICIT IN TWO DIFFERENTIALLY CHALLENGED SOCIAL RECOGNITION TASKS
49. P3‐273: NEUROCHEMICAL AND ELECTROPHYSIOLOGICAL CHARACTERIZATION OF SUVN‐I6107, A NOVEL MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
50. P3‐044: SUVN‐502, A PURE 5‐HT6 RECEPTOR ANTAGONIST, ATTENUATES THE MEMORY DEFICIT CAUSED BY BILATERAL COMMON CAROTID ARTERY LIGATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.